Positives

• Patients exploring mitochondrial peptides for Long COVID fatigue describe MOTS-c as theoretically appealing because mitochondrial dysfunction is increasingly recognized as central to PEM and crash cycles.
  
  
• Some patients on mitochondrial peptide protocols report incremental energy gains over weeks, though responses are inconsistent across the community.
  
  

Negatives

• Patients trying MOTS-c commonly note that human evidence is essentially absent and that benefit is mechanism-extrapolated rather than demonstrated.
  
  
• Some patients describe noticing little or no change after extended use, with the cost not justifying the unclear effect.
  
  

Hurdles & Side Effects

• MOTS-c is sold almost exclusively through grey-market peptide vendors with documented purity problems and contamination risks including heavy metals.
  
  
• Not FDA-approved for any indication; obtaining clinician-supervised access is difficult and most users self-source from research-chemical suppliers.